March 2nd,The 3rd Annual Dermatology Innovation Forum, Orlando
March 3rd-7th, American Academy of Dermatology, Orlando
March 19th-22nd, BIO Europe Spring 2017, Barcelona
May 8th-10th, Bio Trinity, London
May 22nd-23rd, Bio Equity, Paris
May 25th-28th, European Academy of Dermatology and Venereology, Brussels
June 19th-22nd, BIO, San Diego
Edesa Licenses Rights to ASF-1096 for Anorectal Disorders from Cipher Pharmaceuticals Inc.
June 20, 2016 Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 for use in anorectal disorders from Cipher Pharmaceuticals Inc. ASF-1096 is a phase II product candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders. Cipher acquired the global rights to the product in February 2015. Under this agreement, Cipher retains all rights to ASF-1096 for dermatological conditions.
June 6-9: BIO International Conference, San Francisco
May 22-14: Digestive Disease Week, San Diego
March 4-8, American Academy of Dermatology, Washington D.C.
January 11-15: JP Morgan Annual Healthcare Conference, San Francisco
November 2-4: BIO-Europe, Munich, Germany
October 20-21: 14th Annual BIO Investor Forum, San Francisco